JP2025517634A - 上皮増殖因子受容体阻害剤の塩形態及び結晶形態 - Google Patents

上皮増殖因子受容体阻害剤の塩形態及び結晶形態 Download PDF

Info

Publication number
JP2025517634A
JP2025517634A JP2024564833A JP2024564833A JP2025517634A JP 2025517634 A JP2025517634 A JP 2025517634A JP 2024564833 A JP2024564833 A JP 2024564833A JP 2024564833 A JP2024564833 A JP 2024564833A JP 2025517634 A JP2025517634 A JP 2025517634A
Authority
JP
Japan
Prior art keywords
egfr
mesylate salt
ray powder
powder diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517634A5 (cg-RX-API-DMAC7.html
Inventor
グラフ,エリック
クアン,シャンミン
パンディー,アンジャリ
シャー,ハーシュ
シー,ティアン
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2025517634A publication Critical patent/JP2025517634A/ja
Publication of JP2025517634A5 publication Critical patent/JP2025517634A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024564833A 2022-05-04 2023-05-04 上皮増殖因子受容体阻害剤の塩形態及び結晶形態 Pending JP2025517634A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
US63/338,371 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (2)

Publication Number Publication Date
JP2025517634A true JP2025517634A (ja) 2025-06-10
JP2025517634A5 JP2025517634A5 (cg-RX-API-DMAC7.html) 2026-05-12

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564833A Pending JP2025517634A (ja) 2022-05-04 2023-05-04 上皮増殖因子受容体阻害剤の塩形態及び結晶形態

Country Status (12)

Country Link
US (1) US20250282761A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519254A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517634A (cg-RX-API-DMAC7.html)
KR (1) KR20250012078A (cg-RX-API-DMAC7.html)
CN (1) CN119923392A (cg-RX-API-DMAC7.html)
AU (1) AU2023265064A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251624A1 (cg-RX-API-DMAC7.html)
IL (1) IL316663A (cg-RX-API-DMAC7.html)
MX (1) MX2024013485A (cg-RX-API-DMAC7.html)
TW (1) TW202409016A (cg-RX-API-DMAC7.html)
UY (1) UY40256A (cg-RX-API-DMAC7.html)
WO (1) WO2023215431A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202432143A (zh) * 2022-11-01 2024-08-16 美商纜圖藥品公司 用於治療癌症之egfr抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
EP4237418B1 (en) * 2020-10-30 2026-02-11 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof
EP4237088A1 (en) * 2020-10-30 2023-09-06 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
UY40256A (es) 2023-11-15
AU2023265064A1 (en) 2024-11-14
TW202409016A (zh) 2024-03-01
EP4519254A1 (en) 2025-03-12
MX2024013485A (es) 2024-12-06
KR20250012078A (ko) 2025-01-23
WO2023215431A1 (en) 2023-11-09
US20250282761A1 (en) 2025-09-11
CN119923392A (zh) 2025-05-02
IL316663A (en) 2024-12-01
CA3251624A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
TWI753918B (zh) 作為jak抑制劑的吡咯並嘧啶化合物的結晶
CN119654319A (zh) 一种cdk抑制剂及其磷酸盐的多晶型
US9879008B2 (en) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
US9630952B2 (en) Crystalline forms of afatinib di-maleate
EP3986897A1 (en) Egfr inhibitor for the treatment of cancer
WO2019042444A1 (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
JP2011515370A (ja) 4−アミノ−5−フルオロ−3−[5−(4−メチルピペラジン−1−イル)−1h−ベンズイミダゾール−2−イル]キノリン−2(1h)−オン乳酸塩の結晶形態及び2つの溶媒和物形態
WO2016011979A1 (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
TW202136263A (zh) 新穎 egfr 抑制劑
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
CN112119074A (zh) Egfr抑制剂
CN113773305A (zh) 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用
WO2019196938A1 (zh) 喹唑啉类化合物作为egfr三突变抑制剂及其应用
KR20200032152A (ko) N-페닐-2-아미노피리미딘 화합물의 결정형과 염형, 및 이의 제조 방법
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
JP2021529175A (ja) Cdk4/6活性阻害化合物の結晶形およびその使用
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
KR20250038235A (ko) 고체 형태의 jak 억제제 및 이의 제조 공정
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
JP2023505254A (ja) 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドを製造するための方法
WO2019170086A1 (zh) 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260428